Table 1.
Baseline characteristics of the study group: all newly diagnosed previously untreated MDS samples that underwent mutation analysis using 81-gene next-generation sequencing panel.
| Variable | SF3B1 mutated (n=94) | SF3B1 wild-type (n=415) | p-value |
|---|---|---|---|
| Age (years) | 74 (39–92) | 70 (23–93) | 0.0002 |
| Gender (F:M) | 35:59 | 142:273 | 0.63 |
| BM blasts% | 2 (0–16) | 4 (0–19) | 0.003 |
| Hemoglobin (g/dL) | 9.2 (6.9–12.9) | 9.4 (5.2–16.4) | 0.14 |
| MCV fL | 105 (85–117) | 96 (66–122) | <0.0001 |
| Platelet count K/uL | 188 (8–628) | 78 (7–692) | <0.0001 |
| ANC | 2.1 (0.2–6.5) | 1.3 (0–112.9) | 0.76 |
| Chemotherapy | 9 (9.5%) | 122 (29.4%) | 0.0001 |
| Radiation | 11 (11.7%) | 79 (19.0%) | 0.10 |
| Therapy-related | 17 (18%) | 142 (34%) | 0.002 |
| Serum EPO (mIU/mL) | 108 (9–1694) | 56.9 (5.4–5650) | 0.70 |
| Serum Ferritin (ng/mL) | 462 (37–3017) | 462 (24–7261) | 0.47 |
| Morphologic findings | |||
| Ring sideroblasts (%) | 0.4 (0–0.9) | 0.07 (0–0.76) | <0.0001 |
| WHO 2016 sub-classification | |||
| Isolated del(5q) | 4 (4.3%) | 3 (0.7%) | <0.0001 |
| MDS-SLD-RS | 22 (23.4%) | 5 (1.2%) | <0.0001 |
| MDS-MLD | 5 (5.3%) | 137 (33%) | <0.0001 |
| MDS-MLD-RS | 30 (31.9%) | 28 (6.7%) | <0.0001 |
| MDS-EB | 31 (33%) | 201 (48.4%) | <0.0001 |
| MDS-U | 2 (2.1%) | 41 (9.9%) | 0.012 |
| R-IPSS risk categories | |||
| Very High | 12 (12.8%) | 107 (28.8%) | 0.0014 |
| High | 9 (9.6%) | 80 (21.5%) | 0.0079 |
| Intermediate | 13 (13.8%) | 75 (20.2%) | 0.19 |
| Low | 37 (39.4%) | 95 (25.5%) | 0.010 |
| Very Low | 14 (14.9%) | 15 (4%) | 0.0004 |
| IPSS risk categories | |||
| Low | 38 (45.2%) | 69 (18.6%) | <0.0001 |
| Int-1 | 28 (33.3%) | 174 (46.9%) | 0.028 |
| Int-2 | 16 (19%) | 103 (27.8%) | 0.13 |
| High | 2 (2.4%) | 25 (6.7%) | 0.20 |
| Karyotype | |||
| Diploid | 46 (52%) | 136 (35%) | 0.004 |
| Complex karyotype (≥3) | 9 (9.6%) | 133 (36%) | 0.47 |